Coupang Free cash flow decreased by 125.5% to -$112.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 197.4%, from $115.00M to -$112.00M. Over 2 years (FY 2021 to FY 2024), Free cash flow shows an upward trend with a -3.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$137.78M | -$245.42M | -$371.61M | -$293.85M | -$199.03M | -$225.24M | $406.00M | $443.00M | $532.00M | $375.00M | $105.00M | $486.00M | -$46.00M | $462.00M | $115.00M | $246.00M | $439.00M | -$112.00M |
| QoQ Change | — | -78.1% | -51.4% | +20.9% | +32.3% | -13.2% | +280.3% | +9.1% | +20.1% | -29.5% | -72.0% | +362.9% | -109.5% | >999% | -75.1% | +113.9% | +78.5% | -125.5% |
| YoY Change | — | — | — | — | -44.5% | +8.2% | +238.2% | +322.6% | +336.2% | — | -74.1% | +9.7% | -108.6% | +23.2% | +9.5% | -49.4% | >999% | -197.4% |